<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en"><title>News on Takeda Pharmaceutical Co. Ltd.</title><link href="http://diabetesinfoandtreatment.com/topic/takeda-pharmaceutical-co-ltd" rel="alternate"></link><id>http://diabetesinfoandtreatment.com/topic/takeda-pharmaceutical-co-ltd</id><updated>2010-10-24T09:16:56Z</updated><entry><title>New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone</title><link href="http://diabetesinfoandtreatment.com/type-2-diabetes/new-data-showed-type-2-diabetes-patients-experienced-greater-blood-sugar-reductions-treated-actoplus-met-pioglitazone-hcl-metformin-hcl-initial-therapy-compared-component-3012866a" rel="alternate"></link><updated>2010-10-24T09:16:56Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-24:/type-2-diabetes/new-data-showed-type-2-diabetes-patients-experienced-greater-blood-sugar-reductions-treated-actoplus-met-pioglitazone-hcl-metformin-hcl-initial-therapy-compared-component-3012866a/</id><summary type="html">...</summary><category term="Family"></category><category term="Parenting"></category><category term="Eyesight and Eye Health"></category><category term="Kidney Failure"></category><category term="Internal Medicine"></category><category term="Gastrointestinal Disorders"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Hypoglycemia"></category><category term="Type 2 Diabetes"></category><category term="Kidney and Urologic Health"></category><category term="Japan"></category><category term="Asia"></category><category term="American Diabetes Association"></category><category term="Deerfield"></category><category term="East Asia"></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Cardiovascular Medicine"></category><category term="Children's Health"></category><category term="Infant Feeding"></category><category term="Body Weight"></category><category term="Actoplus Met"></category><category term="Robert Spanheimer"></category><category term="Breastfeeding"></category><category term="Current Medical"></category></entry><entry><title>Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and Actos (pioglitazone HCl) for the Treatment of Type 2 Diabetes</title><link href="http://diabetesinfoandtreatment.com/diabetes/takeda-receives-fda-complete-response-letter-investigational-fixeddose-combination-alogliptin-actos-pioglitazone-hcl-treatment-type-2-diabetes-3012086a" rel="alternate"></link><updated>2010-10-24T09:16:21Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-24:/diabetes/takeda-receives-fda-complete-response-letter-investigational-fixeddose-combination-alogliptin-actos-pioglitazone-hcl-treatment-type-2-diabetes-3012086a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Gastrointestinal Disorders"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Japan"></category><category term="Food and Drug Administration"></category><category term="Asia"></category><category term="Actos"></category><category term="Deerfield"></category><category term="East Asia"></category><category term="Osaka"></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Nancy Joseph-Ridge"></category><category term="Cardiovascular Medicine"></category><category term="Infant Feeding"></category><category term="Breastfeeding"></category></entry><entry><title>Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes</title><link href="http://diabetesinfoandtreatment.com/type-2-diabetes/takeda-initiates-cardiovascular-outcomes-trial-alogliptin-investigational-treatment-type-2-diabetes-3011912a" rel="alternate"></link><updated>2010-10-24T09:16:12Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-24:/type-2-diabetes/takeda-initiates-cardiovascular-outcomes-trial-alogliptin-investigational-treatment-type-2-diabetes-3011912a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Gastrointestinal Disorders"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Japan"></category><category term="Food and Drug Administration"></category><category term="Asia"></category><category term="Deerfield"></category><category term="East Asia"></category><category term="Osaka"></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Nancy Joseph-Ridge"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>SYR-322/Actos</title><link href="http://diabetesinfoandtreatment.com/diabetes/syr322actos-3011174a" rel="alternate"></link><updated>2010-10-24T09:15:31Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-24:/diabetes/syr322actos-3011174a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Gastrointestinal Disorders"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Japan"></category><category term="Food and Drug Administration"></category><category term="Asia"></category><category term="Actos"></category><category term="Deerfield"></category><category term="East Asia"></category><category term="Osaka"></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Cardiovascular Medicine"></category><category term="Infant Feeding"></category><category term="Breastfeeding"></category></entry><entry><title>FDA Approves ACTOplus met XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes</title><link href="http://diabetesinfoandtreatment.com/type-2-diabetes/fda-approves-actoplus-met-xr-pioglitazone-hcl-metformin-hcl-extendedrelease-tablets-treatment-type-2-diabetes-3009775a" rel="alternate"></link><updated>2010-10-24T09:14:25Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-24:/type-2-diabetes/fda-approves-actoplus-met-xr-pioglitazone-hcl-metformin-hcl-extendedrelease-tablets-treatment-type-2-diabetes-3009775a/</id><summary type="html">...</summary><category term="Kidney Failure"></category><category term="Internal Medicine"></category><category term="Gastrointestinal Disorders"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Kidney and Urologic Health"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Japan"></category><category term="Food and Drug Administration"></category><category term="Asia"></category><category term="Deerfield"></category><category term="East Asia"></category><category term="Osaka"></category><category term="Watson Pharmaceuticals Inc."></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Cardiovascular Medicine"></category><category term="Actoplus Met"></category></entry><entry><title>Interesting New Data on the Effect of Candesartan on Diabetic Eye Complications</title><link href="http://diabetesinfoandtreatment.com/type-2-diabetes/interesting-new-data-effect-candesartan-diabetic-eye-complications-2948811a" rel="alternate"></link><updated>2010-10-23T16:00:21Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-23:/type-2-diabetes/interesting-new-data-effect-candesartan-diabetic-eye-complications-2948811a/</id><summary type="html">...</summary><category term="Eyesight and Eye Health"></category><category term="Autoimmune Disorders"></category><category term="Vascular Disorders"></category><category term="High Blood Pressure"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 1 Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="European Union"></category><category term="Japan"></category><category term="Italy"></category><category term="Europe"></category><category term="Asia"></category><category term="AstraZeneca Group"></category><category term="The Lancet"></category><category term="Atacand"></category><category term="East Asia"></category><category term="Osaka"></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Southern Europe"></category><category term="Cardiovascular Medicine"></category><category term="Annals of Internal Medicine"></category><category term="Rome (Italy)"></category><category term="European Association of the Study"></category><category term="Masaomi Miyamoto"></category><category term="Kamilla Have Seizo Masuda Takeda Pharmaceuticals Europe Ltd."></category></entry><entry><title>New Data Published in Circulation Showed an Increase in HDL
Cholesterol Levels with Actos (pioglitazone HCl)</title><link href="http://diabetesinfoandtreatment.com/type-2-diabetes/new-data-published-circulation-showed-increase-hdl0Acholesterol-levels-actos-pioglitazone-hcl-2906125a" rel="alternate"></link><updated>2010-10-23T09:20:18Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-23:/type-2-diabetes/new-data-published-circulation-showed-increase-hdl0Acholesterol-levels-actos-pioglitazone-hcl-2906125a/</id><summary type="html">...</summary><category term="Cholesterol"></category><category term="Vascular Disorders"></category><category term="Atherosclerosis"></category><category term="Internal Medicine"></category><category term="Gastrointestinal Disorders"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Chicago"></category><category term="Japan"></category><category term="Asia"></category><category term="Actos"></category><category term="Deerfield"></category><category term="East Asia"></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Cardiovascular Medicine"></category></entry></feed>
